BioPharma Resources

Drug Trial Radar · NCT07346495

A Study of Remternetug (LY3372993) in Healthy Chinese Participants

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of Remternetug in Healthy Chinese Participants

Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Jan 31, 2026

Primary completion

Aug 4, 2026

Study completion Aug 4, 2026

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Jan 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study will evaluate the safety and tolerability of remternetug when given subcutaneously (SC) (under the skin) to healthy Chinese participants. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last up to 25 weeks, including screening period.

Conditions

  • Healthy

Interventions

  • LY3372993Drug

    Administered SC

  • PlaceboDrug

    Administered SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationTime frame: Baseline through study completion up to 25 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Xuanwu Hospital Capital Medical University

    Beijing, China

  • Shanghai Xuhui Central Hospital

    Xuhui District, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.